Salivary gland function in thyroid cancer patients with radioiodine administration history

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11150%2F20%3A10399105" target="_blank" >RIV/00216208:11150/20:10399105 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/00179906:_____/20:10399105

Výsledek na webu

<a href="https://verso.is.cuni.cz/pub/verso.fpl?fname=obd_publikace_handle&handle=CTs5VxhMgq" target="_blank" >https://verso.is.cuni.cz/pub/verso.fpl?fname=obd_publikace_handle&handle=CTs5VxhMgq</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.5507/bp.2019.023" target="_blank" >10.5507/bp.2019.023</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Salivary gland function in thyroid cancer patients with radioiodine administration history

Popis výsledku v původním jazyce

AIM:Radioiodine (RAI) improves survival in patients with locally advanced or metastatic differentiated thyroid carcinoma (DTC). Although there has been an ongoing debate on RAI-induced salivary gland damage, published data have been inconsistent. Therefore, the purpose of our study was to compare salivary gland function in intermediate and high risk DTC patients after single or repeated RAI treatment with their age- and sex-matched RAI-naive counterparts.METHODS:Uptake and excretion of parotid and submandibular glands were quantitatively evaluated using 99mTc-pertechnetate salivary gland scintigraphy in 23 patients previously treated with RAI. Patients (median 9.25 GBq 131I-NaI; Q1-Q3: 5.55-16.65; range: 5.55-27.5) were divided into subgroups according to previously administered 131I-NaI activity using cut-off values 5.55 GBq and 9.25 GBq. Their salivary gland scintigraphy results were compared with RAI-naive patients using Mann-Whitney test.RESULTS:Compared to RAI-naive patients, parotid glands pertechnetate uptake was significantly lower in those treated with &gt; 9.25 GBq (P=0.034) and parotid glands excretion fraction was already decreased with RAI activities &gt; 5.55 GBq (P=0.031). In submandibular glands, no statistically significant difference in either function was observed even with RAI activity &gt; 9.25 GBq.CONCLUSION:Our data suggest that RAI therapy using activities &lt;= 5.55 GBq does not substantially decrease saliva production. Activities &gt; 5.55 GBq may lead to significant decrease in parotid excretion, and activities &gt; 9.25 GBq also diminish parotid uptake. Surprisingly, submandibular glands, providing majority of seromucinous saliva under basal condition, seem to be unaffected even by RAI activities above 9.25 GBq.

Název v anglickém jazyce

Salivary gland function in thyroid cancer patients with radioiodine administration history

Popis výsledku anglicky

AIM:Radioiodine (RAI) improves survival in patients with locally advanced or metastatic differentiated thyroid carcinoma (DTC). Although there has been an ongoing debate on RAI-induced salivary gland damage, published data have been inconsistent. Therefore, the purpose of our study was to compare salivary gland function in intermediate and high risk DTC patients after single or repeated RAI treatment with their age- and sex-matched RAI-naive counterparts.METHODS:Uptake and excretion of parotid and submandibular glands were quantitatively evaluated using 99mTc-pertechnetate salivary gland scintigraphy in 23 patients previously treated with RAI. Patients (median 9.25 GBq 131I-NaI; Q1-Q3: 5.55-16.65; range: 5.55-27.5) were divided into subgroups according to previously administered 131I-NaI activity using cut-off values 5.55 GBq and 9.25 GBq. Their salivary gland scintigraphy results were compared with RAI-naive patients using Mann-Whitney test.RESULTS:Compared to RAI-naive patients, parotid glands pertechnetate uptake was significantly lower in those treated with &gt; 9.25 GBq (P=0.034) and parotid glands excretion fraction was already decreased with RAI activities &gt; 5.55 GBq (P=0.031). In submandibular glands, no statistically significant difference in either function was observed even with RAI activity &gt; 9.25 GBq.CONCLUSION:Our data suggest that RAI therapy using activities &lt;= 5.55 GBq does not substantially decrease saliva production. Activities &gt; 5.55 GBq may lead to significant decrease in parotid excretion, and activities &gt; 9.25 GBq also diminish parotid uptake. Surprisingly, submandibular glands, providing majority of seromucinous saliva under basal condition, seem to be unaffected even by RAI activities above 9.25 GBq.

Druh

J_imp - Článek v periodiku v databázi Web of Science

CEP obor

—

OECD FORD obor

30202 - Endocrinology and metabolism (including diabetes, hormones)

Projekt

—

Návaznosti

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Rok uplatnění

2020

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Biomedical Papers

ISSN

1213-8118

e-ISSN

—

Svazek periodika

164

Číslo periodika v rámci svazku

3

Stát vydavatele periodika

CZ - Česká republika

Počet stran výsledku

7

Strana od-do

277-283

Kód UT WoS článku

000595645600009

EID výsledku v databázi Scopus

2-s2.0-85091166799